Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05711732 · ClinicalTrials.gov registry record
Busulfan Sample Collection Study
A clinical trial of Subjects Treated With Busulfan, sponsored by Saladax Biomedical.
- Recruiting
- Registry status
- 150
- Enrollment target
- 2
- Study locations
NCT05711732: Recruiting study of Subjects Treated With Busulfan, sponsored by Saladax Biomedical.
NCT05711732 is a study of Subjects Treated With Busulfan that is actively recruiting participants, run by Saladax Biomedical. The registered enrollment target is 150 participants. The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05711732, a study of Subjects Treated With Busulfan, is actively recruiting participants, sponsored by Saladax Biomedical.
- RECRUITING
- Registry status
- 150 participants
- Enrollment target
- 2
- Study locations
Study Summary
Busulfan (Busulfex®) is an alkylating drug used as a conditioning regimen prior to allogeneic hematopoietic stem cell transplantation. Busulfan has wide inter- and intra-patient pharmacokinetic variability resulting in variable exposure leading to increased risk of toxicities or sub-optimal treatment outcomes. Therapeutic drug monitoring of busulfan using patient plasma samples would benefit clinicians by providing the ability to personalize the dose to achieve a target busulfan exposure.
Primary Outcome
The samples being collected according to the protocol, SBI-BSI-001, will be used to compare the quantitate determination of BSF in patient samples based on the immunoassay vs. LC-MS/MS methods .
Conditions Studied
Interventions
- DIAGNOSTIC_TEST MyCare Oncology Busulfan Assay Kit
Study Locations (2)
Illinois
- Robert H. Lurie Comprehensive Cancer Center of Northwestern University - Chicago
Texas
- The University of Texas MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2024-02-08 |
| Est. Completion | 2026-01-31 |
What NCT05711732 shows while recruiting
NCT05711732 is an observational study that tracks outcomes without assigning an intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap.
The record links to 1 condition, with Subjects Treated With Busulfan appearing as the primary indexed condition, and to 1 intervention - of which MyCare Oncology Busulfan Assay Kit is the first listed.
NCT05711732 reports a single indexed study location in Illinois, Texas.
Frequently Asked Questions
What is clinical trial NCT05711732 about?
NCT05711732 is a clinical study titled "Busulfan Sample Collection Study". Busulfan (Busulfex®) is an alkylating drug used as a conditioning regimen prior to allogeneic hematopoietic stem cell transplantation. Busulfan has wide inter- and intra-patient pharmacokinetic variability resulting in variable exposure leading to increased risk of toxicities or sub-optimal treatmen...
What is the current status of trial NCT05711732?
This trial is currently recruiting. The enrollment target is 150 participants. The study started on 2024-02-08. Estimated completion is 2026-01-31.
What conditions does trial NCT05711732 study?
This clinical trial studies the following conditions: Subjects Treated With Busulfan.
What interventions are being tested in trial NCT05711732?
The interventions under investigation include: MyCare Oncology Busulfan Assay Kit (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT05711732?
This trial is sponsored by Saladax Biomedical, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05711732 being conducted?
This trial has 2 study locations across Illinois, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
- NCT01985919 · 150 participants
Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples
- NCT02016248 · 150 participants · NA
SBRT Boost for Unfavorable Prostate Cancer'
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI